BioGaia AB ser. B (0GTN)
London Exchange · UK · prices in SEK · close of 15 Oct 2026
Key indicators
| Last close | SEK 122.60 |
|---|---|
| 52-week range | 95.06 – 136.20 |
| Return, 1 month / 3 months | +14.5% / −0.1% |
| Return, 1 year / 3 years | +14.9% / +36.9% |
| Trend | Uptrend |
| RSI (14) | 70 |
| Volatility (1 year) | 26.8% |
| Worst drawdown (1 year) | -20.9% |
| Average daily value traded | 1.38M SEK |
| Dividend yield | 1.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
BioGaia AB is a Swedish company that develops and markets probiotic products based on lactic acid bacteria, chiefly strains of Lactobacillus reuteri. Its consumer products include drops, tablets and sachets aimed at digestive health, with a particular focus on infants and children, and it also supplies probiotic cultures and ingredients to food and supplement makers. The company is based in Stockholm and sells its products through partners and distributors in many countries.
On this site BioGaia AB ser. B appears as a stock on the London Exchange (UK), code 0GTN, with prices in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
BioGaia AB ser. B (0GTN) trades on the London Exchange in UK. It last closed at SEK 122.60 on 15 October 2026.
Its price-based Market X-Ray is 58 out of 100 (a fair price profile), ranking 1,538 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 14.9% and over the last three months it fell 0.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 59 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 6.8% | ||
| From 52-week high | -9.4% | ||
| Momentum | 50 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -0.1% | ||
| 6-month return | 3.2% | ||
| 12-month return, skipping the last month | 0.3% | ||
| Stability (higher is calmer) | 71 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 26.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -20.9% | ||
| Liquidity | 56 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.38M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | 47 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.3% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | +6.1% |
|---|---|
| 1 month | +14.5% |
| 3 months | −0.1% |
| 6 months | +3.2% |
| 1 year | +14.9% |
| 3 years | +36.9% |
| 5 years | – |
Signals
| 50-day / 200-day average | 113.55 / 114.79 |
|---|---|
| Golden / death cross (60 days) | Death, 13 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.01 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 8 May 2026 | SEK 1.6400 |
| 8 May 2025 | SEK 4.9500 |
| 8 May 2024 | SEK 5.0000 |
| 8 May 2023 | SEK 1.4500 |
| 9 May 2022 | SEK 3.6300 |
| 7 May 2021 | SEK 3.4100 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.